LVMUY-OTC 0 ACN-N -0.98 UNH-N -4.91 VALT-T 0.19 MART-T -0.15 VIDY-T 0.31 RPRX-Q 0.05
Daily Stock Opinions and Ratings
Stockchase Opinions

Brian Acker, CA King Pharmaceuticals KG-N DON'T BUY Nov 07, 2002

Fundamentally should be good, but the stock languishes.
Brian Acker, CABrian Acker, CA
Unknown
Unlock Rating
$15.910

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

BUY

King Pharmaceuticals(KG-N)

Aug 16, 2002
Cheap/ Good growth prospects. Only own a small portion in your portfolio.
Robert FloydRobert Floyd
Unknown
Unlock Rating
$19.380

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

King Pharmaceuticals(KG-N)

Jul 14, 2003
Systems indicate a top pick. Cheap and has earnings.
Brian Acker, CABrian Acker, CA
Unknown
Unlock Rating
$16.250

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

King Pharmaceuticals(KG-N)

Aug 12, 2003
(Was a top pick on July 14, 2003.Up 15%.)Still likes.Good earnings. Came out with a relatively good performance report.Got hit by a sudden move of defense money moving into cyclical areas.Got too cheap.
Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$13.920

Stock price when the opinion was issued

biotechnology pharmaceutical
WEAK BUY

King Pharmaceuticals(KG-N)

Aug 22, 2003
Generic drug makers have been on quite a role.A good group to have exposure to.This company has FCC and business model problems.Risky.
Matt BaraschMatt Barasch
Unknown
Unlock Rating
$13.970

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

King Pharmaceuticals(KG-N)

Sep 03, 2003
Will be volatile. An OK company at a bargain price. Good risk/reward.
Peter Arender, CFAPeter Arender, CFA
Owned
Unlock Rating
$14.200

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

King Pharmaceuticals(KG-N)

Sep 15, 2003
Has great value. US Healthcare looks very inexpensive.
Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$16.120

Stock price when the opinion was issued

biotechnology pharmaceutical
PAST TOP PICK

King Pharmaceuticals(KG-N)

Sep 25, 2003
(A top pick Aug 12/03. Up 3%.) Still likes. An outstanding value for investors to focus on.
Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$15.250

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

King Pharmaceuticals(KG-N)

Dec 19, 2003
Technical support is $12.75. A lot of upside potential. Fair market value is $35/40. However, earnings forecast trend is in a decline.
Ross HealyRoss Healy
Unknown
Unlock Rating
$14.680

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

King Pharmaceuticals(KG-N)

Apr 30, 2004
A potential takeover play. Has been a bit undermanaged and is very cheap.
David KingDavid King
Unknown
Unlock Rating
$17.250

Stock price when the opinion was issued

biotechnology pharmaceutical

Build our watch list

Sign in to track investments
you care about

Latest Buy Signals

AAXN-Q -2.24$684.59
RKLB-Q -2.59$20.51
ENB-T 0.51$64.3
CLF-N -0.15$7
PLTR-Q -1.85$117.3

Today's Top Picks

LVMUY-… 0$109.799
ACN-N -0.98$307.9
UNH-N -4.91$380.64
VALT-T 0.19$40.79
MART-T -0.15$22.75

Popular Articles

Latest Sell Signals

GOOG-Q -1.37$154.38
VRTX-Q -4.61$424.99
PLTR-Q -1.85$117.3
ZTS-N -2.42$159.27
ADBE-Q -0.71$383.28

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Michael Hakes - CFA, MBA

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brenda Vingiello, CIO, Sand Hill Global Advisors

Brenda Vingiello, CIO, Sand Hill Global Advisors

Sand Hill Global Advisors

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica